ArticleThe Pan African medical journal2026
Modified cetyltrimethylammonium bromide DNA extraction for
Article in The Pan African medical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Efficient extraction of high-quality genomic deoxyribonucleic acid (DNA) from Mycobacterium tuberculosis (MTB) is a critical step for whole genome sequencing (WGS) and downstream molecular applications. However, the lipid-rich MTB cell wall continues to limit DNA recovery, and existing protocols do not consistently address this challenge. This study aimed to refine the cetyltrimethylammonium bromide (CTAB)-based DNA extraction protocol to achieve improved DNA yield and purity for downstream WGS applications. We conducted a cross-sectional laboratory-based protocol refinement study nested within an ongoing MTBC genetic diversity and drug resistance study in western Kenya, using archived Mycobacterium Growth Indicator Tube (MGIT) cultured isolates. The entire MGIT broth from the MTBC-positive isolates was centrifuged before extraction to maximize bacterial biomass recovery, followed by an extended lysozyme incubation to promote enzymatic cell wall disruption. The process combined enzymatic lysis, mechanical disruption, CTAB-based purification, and isopropanol precipitation. Deoxyribonucleic acid concentration and purity were determined by NanoDrop spectrophotometry. A total of 325 MTB isolates were processed. Deoxyribonucleic acid (DNA) concentrations ranged from 5.41 to 2,052.60 ng/μL (median: 65.21 ng/μL), with A260/280 purity ratios between 1.36 and 2.08. 60% of samples achieved DNA concentrations ≥50 ng/μL, and overall, 89% (290/325) of the samples successfully passed sequencing quality control. The majority of the samples were successfully sequenced. The refined CTAB protocol effectively overcomes the challenge posed by the MTB cell wall, yielding high-quality DNA suitable for WGS. It provides an accessible and scalable approach for laboratories in high TB burden and resource-limited settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.